Phosphorus is an important element for normal physiologic functions such as bone construction, nerve function, and muscle contraction. About 85% of phosphorus is stored in the bones and different tissues in the body. The excess phosphorus is eliminated from the body by the urinary system. The normal phosphate level in the blood is 3-4 mg/dL. Electrolytic disturbance resulting in high levels of phosphate in the blood causes hyperphosphatemia. Individuals with chronic kidney diseases have a decreased glomerular filtration rate and increased serum phosphate levels. The high phosphate levels in the serum lower calcium levels because of phosphate precipitation by calcium ions, leading to calcification of vascular tissues and heart diseases. Aluminum-, calcium-, magnesium-, and iron-based and aluminum-free, calcium-free phosphate binders are used to treat the condition.
Technavio's analysts forecast the global hyperphosphatemia drugs market to grow at a CAGR of 10.71% over the period 2014-2019.
Covered in this Report
In this report, Technavio covers the present scenario and growth prospects of the global hyperphosphatemia drugs market for 2015-2019. To calculate the market size, the report considers revenue generated from the sales of branded, generic, OTC, and off-label drugs used for treating hyperphosphatemia.
Technavio's report, Global Hyperphosphatemia Drugs Market 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, APAC, and EMEA; it also covers the landscape of the global hyperphosphatemia drugs market and its growth prospects in the coming years. The report includes a discussion of the key vendors operating in this market.
Key regions
PART 01: Executive summary
Highlights
PART 02: Scope of the report
Market overview
Top-vendor offerings
PART 03: Market research methodology
Research methodology
Economic indicators
PART 04: Product profiles
Request A Sample copy of This Report @ http://www.hexareports.com/sample/45939
PART 05: Introduction
Key market highlights
PART 06: Disease Overview
Understanding the disease
Etiology
Effects of hyperphosphatemia
Causes
Signs and symptoms
Diagnosis
Management
Epidemiology
PART 07: Key developments in hyperphosphatemia therapy
PART 08: Guidelines for use of phosphate binders
CKD stages 2-4
CKD stage 5
PART 09: Pipeline analysis
Information on pipeline candidates
PART 10: Market landscape
Market overview
Market size and forecast
Five forces analysis
PART 11: Hyperphosphatemia management market dynamics
PART 12: Market segmentation by dosage form
Solid
Liquid
Browse Full Report @ http://www.hexareports.com/report/global-hyperphosphatemia-drugs-market-2015-2019/details
About Us:
Hexa Reports is a market research and consulting organization, offering industry reports, custom research and consulting services to a host of key industries across the globe. We offer comprehensive business intelligence in the form of industry reports which help our clients obtain clarity about their business environment and enable them to undertake strategic growth initiatives.
Contact Information:
Ryan Shaw
Felton Office Plaza,
6265 Highway 9,
Felton, California, 95018,
United States
Phone Number
1-800-489-3075
Email Us: sales@hexareports.com
Our Website: http://www.hexareports.com/
Technavio's analysts forecast the global hyperphosphatemia drugs market to grow at a CAGR of 10.71% over the period 2014-2019.
Covered in this Report
In this report, Technavio covers the present scenario and growth prospects of the global hyperphosphatemia drugs market for 2015-2019. To calculate the market size, the report considers revenue generated from the sales of branded, generic, OTC, and off-label drugs used for treating hyperphosphatemia.
Technavio's report, Global Hyperphosphatemia Drugs Market 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, APAC, and EMEA; it also covers the landscape of the global hyperphosphatemia drugs market and its growth prospects in the coming years. The report includes a discussion of the key vendors operating in this market.
Key regions
- Americas
- APAC
- EMEA
- Fresenius Medical Care
- Keryx Biopharmaceuticals
- Sanofi
- Shire
- Vifor Pharma
- Alkem
- Amgen
- Ardelyx
- AstraZeneca
- Baxter
- Bayer
- Chugai Pharmaceutical
- Japan Tobacco
- Kissei Pharmaceutical
- Kyowa Hakko Kirin
- Mylan
- Natco
- Novartis
- Opko Health
- Panion & BF Biotech
- Roxane Laboratories
- Sandoz
- Synthon
- Torri Pharmaceutical
- Increased number of people undergoing dialysis
- For a full, detailed list, view our report
- Non-adherence to treatment regimens
- For a full, detailed list, view our report
- Patient assistance programs
- For a full, detailed list, view our report
- What will the market size be in 2019 and what will the growth rate be?
- What are the key market trends?
- What is driving this market?
- What are the challenges to market growth?
- Who are the key vendors in this market space?
- What are the market opportunities and threats faced by the key vendors?
- What are the strengths and weaknesses of the key vendors?
PART 01: Executive summary
Highlights
PART 02: Scope of the report
Market overview
Top-vendor offerings
PART 03: Market research methodology
Research methodology
Economic indicators
PART 04: Product profiles
Request A Sample copy of This Report @ http://www.hexareports.com/sample/45939
PART 05: Introduction
Key market highlights
PART 06: Disease Overview
Understanding the disease
Etiology
Effects of hyperphosphatemia
Causes
Signs and symptoms
Diagnosis
Management
Epidemiology
PART 07: Key developments in hyperphosphatemia therapy
PART 08: Guidelines for use of phosphate binders
CKD stages 2-4
CKD stage 5
PART 09: Pipeline analysis
Information on pipeline candidates
PART 10: Market landscape
Market overview
Market size and forecast
Five forces analysis
PART 11: Hyperphosphatemia management market dynamics
PART 12: Market segmentation by dosage form
Solid
Liquid
Browse Full Report @ http://www.hexareports.com/report/global-hyperphosphatemia-drugs-market-2015-2019/details
About Us:
Hexa Reports is a market research and consulting organization, offering industry reports, custom research and consulting services to a host of key industries across the globe. We offer comprehensive business intelligence in the form of industry reports which help our clients obtain clarity about their business environment and enable them to undertake strategic growth initiatives.
Contact Information:
Ryan Shaw
Felton Office Plaza,
6265 Highway 9,
Felton, California, 95018,
United States
Phone Number
1-800-489-3075
Email Us: sales@hexareports.com
Our Website: http://www.hexareports.com/
No comments:
Post a Comment